Relationship between the CYP2C19 polymorphism and the efficacy of triple therapy with lansoprazole onHelicobacter pylori infection in elderly patients

VernacularTitle:老年患者细胞色素P4502C19基因多态性与兰索拉唑三联疗法根除幽门螺杆菌疗效的关系
Author: Junli XU ; Yujie FANG ; Yongguo LIU ; Mingli ZHANG ; Songdi WU ; Yali CUI
Publication Type:Journal Article
Keywords: Iansoprazole; CytochromeP-450 Enzyme; Polymorphism
From: The Journal of Practical Medicine 2014;(20):3242-3244
CountryChina
Language:Chinese
Abstract: Objective To investigate the Relationship between the CYP2C19 polymorphism and the efficacy of triple therapy with lansoprazole on Helicobacter pylori infection. Methods 125 elderly patients diagnosed with H.pylori infection were treated with triple therapy. Polymorphism of CYP2C19 was measured by AS-PCR. 105 young patients were selected as control group. The relationship between the polymorphism and eradication rate were analyzed. Results Among the 125 patients,eradication rate of extensive metabolizer group,internal metabolizer group and poor metabolizer groups was 85.29%,76%and 89.39%, respectively. There was no significant difference between groups (P > 0.05). Eradication rate showed no difference between experimental and control group either (P>0.05)(P>0.05). Conclusion The results suggests that the CYP2C19 polymorphism has no correlation with the eradication rate of Helicobacter pylori infection by triple therapy with lansoprazole in elderly patients.